+1 (619) 956-9114 info@myicfos.com
Follow us

iCFO Capital Global partnered with Nob Hill Therapeutics to raise $3M in a convertible note.

February 14, 2024 by
iCFO Capital Global partnered with Nob Hill Therapeutics to raise $3M in a convertible note.
Alejandra Rosas

SAN DIEGO, CALIFORNIA - iCFO Capital Global, Inc., partnered with Nob Hill Therapeutics (NHT) to raise $3M in a convertible note from iCFO Capital Global investor network nationwide.

NHT is a healthcare startup that is developing new technologies and therapies for lung-related diseases that can’t be effectively treated today.  These diseases impact millions of patients, and the annual market potential for several of these diseases is substantial (e.g., lung cancer - $30b, Cystic Fibrosis - $13b, Invasive fungal infections - $9b).  NHT has developed a new drug inhalation device platform that solves many disadvantages with today’s technologies. The company also is working on accompanying drug-device combination products that will treat leading causes of death and serve as proof of concept for the technology platform (with addressable US markets of $1.75b annual sales). NHT’s team is highly experienced with developing and commercializing respiratory products (combined experience of 100+ years).

NHT’s new inhalation technology is a first-of-its-kind dry powder nebulizer (DryNeb) drug delivery platform that can deliver high-dose payloads to a patient’s lungs (much more than a typical inhaler) while the patient breathes normally. The platform technology can be used with many different medicines and has the potential to treat several diseases that present unmet medical needs for patients, such as lower respiratory infections (#3 leading cause of death globally) and lung cancer (#1 leading cause of cancer death)

The company has achieved several key milestones, including winning three (3) SBIR grants worth $4M. Two of these grants have helped fund work on NHT’s technology platform and on an inhaled anti-fungal medicine. The third grant is helping fund the development of a lung cancer medicine. NHT is now seeking private funds of $3M to complement these grants. These additional funds will be used to finalize the clinical version of the device platform, conduct the technology’s first in- human study, and also to help conduct early studies on the lung cancer medicine.

Noel Greenberger is the CEO of Nob Hill Therapeutics. Previously, Noel was the Chief Commercial Officer of Vertice Pharma, a private equity-backed specialty pharmaceutical company.  Before Vertice, he was at Novartis as the Executive Director of Respiratory at Sandoz U.S., and he also worked at McKinsey & Company in its healthcare practice.  Noel holds an MBA from The Wharton School and a Bachelor of Science in Industrial Engineering from Northwestern University. 

For more information about the company, visit: https://nobhilltherapeutics.com/

iCFO Capital Global, Inc. provides a platform for Entrepreneurs to connect with our Private Investors that makes direct debt and equity investment for early-stage and expand growth businesses. To learn more about how your business can secure the funding it needs, visit: https://www.icfocapital.com/

Schedchule a meeting with our Managing Director, Khris Thetsy at the following link: https://calendly.com/icfo-khristhetsy